ADVFN - Advanced Financial Network.
HOME» NYSE » O » OCR Stock Price » OCR Stock News

Omnicare Share News

 Omnicare Inc. Stock Price
OCR Stock Price
 Omnicare Inc. Stock Chart
OCR Stock Chart
 Omnicare Inc. Stock News
OCR Stock News
 Omnicare Inc. Company Information
OCR Company Information
 Omnicare Inc. Stock Trades
OCR Stock Trades

Omnicare Taps McKesson Drug Wholesale Executive As New CEO

By Dinah Wisenberg Brin Of DOW JONES NEWSWIRES Nursing-home pharmacy Omnicare Inc. (OCR) tapped drug-distribution industry veteran John Figueroa to be its chief executive, effective Jan. 1, boosting the company's shares Wednesday. Figueroa, who has been serving as president of drug wholesaler McKesson Corp.'s (MCK) pharmaceutical group, replaces James Shelton, who became Omnicare's interim president and CEO in August following the sudden departure of longtime CEO Joel Gemunder. Figueroa, who also will become a member of Omnicare's board, will lead a company that has seen a difficult 2010, including a sharp second-quarter profit drop tied to lower prescription volume, weakened share price, a downgrade from Moody's Investors Service, a management shakeup and the unsealing of a lawsuit alleging Omnicare submitted false claims to government health programs. Omnicare has denied those fraud allegations. McKesson, the largest U.S. drug distributor by revenue and market cap, on Wednesday named Brian Tyler, current head of its medical-surgical business, to replace Figueroa as president of that company's pharmaceutical group, effective Jan. 1. Omnicare shares recently traded up 4% at $23.94, while McKesson slipped 1% to $66.15. "John Figueroa is an excellent hire for Omnicare," said JP Morgan analyst Lisa Gill, noting that McKesson has expanded its drug-distribution margins to be the highest in that industry under his leadership in the past five years. Omnicare is a long-time McKesson client, so Figueroa should be well aware of the company's potential, she said. His strong background with a solid company "should give investors confidence that OCR's business model can attract strong management," said Gill. As for McKesson, Barclays Capital analyst Lawrence Marsh noted Tyler's many years of experience. His appointment "validates the quality and experience of senior managers at McKesson under Chairman and CEO John Hammergren," Marsh said. Tyler brings deep experience in a variety of roles at McKesson, so the transition should be smooth, with continued strong performance in the business, Robert W. Baird analyst Eric Coldwell said. -By Dinah Wisenberg Brin, Dow Jones Newswires, 215-656-8285;

Stock News for Omnicare (OCR)
03/25/201409:41:12U.S. Hot Stocks: Hot Stocks to Watch
02/19/201409:51:22U.S. Stocks: Hot Stocks to Watch
12/05/201309:04:04U.S. Hot Stocks Futures: Hot Stocks to Watch
11/15/201309:18:03OZ Management LP 3Q 13F: Largest Purchases -2-
11/15/201309:18:02OZ Management LP 3Q 13F: Holdings As Of Sep 30
11/15/201309:18:02OZ Management LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201309:18:02OZ Management LP 3Q 13F: Largest Purchases
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201308:21:52Janus Capital Management 3Q 13F: Largest Purchases -2-
11/15/201308:21:50Janus Capital Management 3Q 13F: Largest Sales
11/15/201307:11:08AQR Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201307:11:08AQR Capital Management 3Q 13F: Holdings As Of Sep -2-
04/16/201317:30:14Amgen to Pay $24.9 Million to Settle Kickbacks Allegations
04/16/201317:23:12Amgen to Pay $24.9 Million to Settle U.S. Allegations of Kickbacks
01/30/201309:49:57AmerisourceBergen Signs New Deal With Big Customer PharMerica
06/08/201218:10:09J&J to Record $600 Million Charge in 2Q
06/08/201218:03:22J&J to Record $600 Million Charge Tied to Outstanding Lawsuits
04/25/201217:16:50J&J New CEO: Top Job Is Fixing Over-The-Counter Drug Business
04/13/201214:10:39US Wants To Question Incoming J&J CEO In Kickback Lawsuit

Omnicare and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations